Armin Scherhag

6.1k total citations · 2 hit papers
60 papers, 4.4k citations indexed

About

Armin Scherhag is a scholar working on Cardiology and Cardiovascular Medicine, Hematology and Surgery. According to data from OpenAlex, Armin Scherhag has authored 60 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Cardiology and Cardiovascular Medicine, 17 papers in Hematology and 12 papers in Surgery. Recurrent topics in Armin Scherhag's work include Erythropoietin and Anemia Treatment (17 papers), Heart Failure Treatment and Management (17 papers) and Cardiovascular Function and Risk Factors (9 papers). Armin Scherhag is often cited by papers focused on Erythropoietin and Anemia Treatment (17 papers), Heart Failure Treatment and Management (17 papers) and Cardiovascular Function and Risk Factors (9 papers). Armin Scherhag collaborates with scholars based in Germany, Switzerland and United Kingdom. Armin Scherhag's co-authors include Hans-Ulrich Burger, Francesco Locatelli, Kai‐Uwe Eckardt, Dimitrios Tsakiris, Naomi Clyne, Tilman B. Drüeke, Iain C. Macdougall, Willem J. Remme, Michel Komajda and Marco Metra and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Armin Scherhag

60 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia

2006 1.5k citations Tilman B. Drüeke, Francesco Locatelli et al. New England Journal of Medicine profile →
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial

2003 1.3k citations Philip A. Poole‐Wilson, Karl Swedberg et al. profile →

Peers

Countries citing papers authored by Armin Scherhag

Since Specialization

Citations

This map shows the geographic impact of Armin Scherhag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Armin Scherhag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Armin Scherhag more than expected).

Fields of papers citing papers by Armin Scherhag

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Armin Scherhag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Armin Scherhag. The network helps show where Armin Scherhag may publish in the future.

Co-authorship network of co-authors of Armin Scherhag

This figure shows the co-authorship network connecting the top 25 collaborators of Armin Scherhag. A scholar is included among the top collaborators of Armin Scherhag based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Armin Scherhag. Armin Scherhag is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Characterization of New Organic Nitrate Hybrid Drugs Covalently Bound to Valsartan and Cilostazol 2012 ·Pharmacology ·Maike Knorr, Michael Hausding, Eberhard Schulz, Matthias Oelze, (unknown), A Schuff, Steffen Daub, (unknown), Swenja Kröller‐Schön, Philip Wenzel, Tommaso Gori, (unknown), (unknown), Armin Scherhag, Thomas Münzel, Andreas Daiber	6
2	Epoetin-β treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events 2009 ·British Journal of Cancer ·Matti Aapro, B Osterwalder, Armin Scherhag, Hans-Ulrich Burger	37
3	Prognostic Importance of Plasma NT-Pro BNP in Chronic Heart Failure in Patients Treated with a β-blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) Trial 2007 ·European Journal of Heart Failure ·Lars Olsson, Karl Swedberg, John G.F. Cleland, (unknown), Michel Komajda, Marco Metra, Christian Torp‐Pedersen, Willem J. Remme, Armin Scherhag, Philip Poole‐Wilson, (unknown)	60
4	Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia breakdown → 2006 ·New England Journal of Medicine ·Tilman B. Drüeke, Francesco Locatelli, Naomi Clyne, Kai‐Uwe Eckardt, Iain C. Macdougall, Dimitrios Tsakiris, Hans-Ulrich Burger, Armin Scherhag	1470
5	Exchange of β-Blockers in Heart Failure Patients. Experiences from the Poststudy Phase of COMET (the Carvedilol or Metoprolol European Trial) 2005 ·European Journal of Heart Failure ·Andrea Di Lenarda, Willem J. Remme, Andrew Charlesworth, John G.F. Cleland, Beatrix Lutiger, Marco Metra, Michel Komajda, Christian Torp‐Pedersen, Armin Scherhag, Karl Swedberg, Philip A. Poole‐Wilson, (unknown)	27
6	Proven Strategies to Reduce Cardiovascular Mortality in Hemodialysis Patients 2005 ·Blood Purification ·H. Hampl, (unknown), Christian Rosenberger, (unknown), Eberhard Riedel, Armin Scherhag	3
7	Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure—COMET 2005 ·American Heart Journal ·Christian Torp‐Pedersen, Philip A. Poole‐Wilson, Karl Swedberg, John G.F. Cleland, Andrea Di Lenarda, Peter Hanrath, Michel Komajda, Beatrix Lutiger, Marco Metra, Willem J. Remme, Armin Scherhag, Allan M. Skene	67
8	Automated Impedance Cardiography for Detecting Ischemic Left Ventricular Dysfunction during Exercise Testing 2005 ·Kidney & Blood Pressure Research ·Armin Scherhag, Stefan Pfleger, (unknown), J. Buss, Tim Sueselbeck, Martin Borggrefe	6
9	Effects of Optimized Heart Failure Therapy and Anemia Correction with Epoetin β on Left Ventricular Mass in Hemodialysis Patients 2005 ·American Journal of Nephrology ·Hannelore Hampl, (unknown), Christian Rosenberger, (unknown), (unknown), Eberhard Riedel, Armin Scherhag	32
10	Tolerability of Carvedilol and ACE-Inhibition in Mild Heart Failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN) 2004 ·European Journal of Heart Failure ·Michel Komajda, Beatrix Lutiger, Hugo Madeira, Kristian Thygesen, Marco Bobbio, Per Hildebrandt, Wybren Jaarsma, Günter A.J. Riegger, Lars Rydén, Armin Scherhag, Jordi Soler‐Soler, Willem J. Remme	55
11	1001-26 Exchange of beta-blocking therapy in heart failure patients. Experiences from the post study phase of COMET (the carvedilol or metoprolol European trial) 2004 ·Journal of the American College of Cardiology ·Andrea Di Lenarda, Philip A. Poole‐Wilson, John G.F. Cleland, Peter Hanrath, Michel Komajda, Jacobus Lubsen, Beatrix Lutiger, Marco Metra, Willem J. Remme, Armin Scherhag, Andrew Charlesworth, Christian Torp‐Pedersen	2
12	835-3 Beta-blocker dose does not influence the beneficial effects of carvedilol compared to metroprolol in the patients with heart failure: Results from the carvedilol or Metoprolol European Trial (COMET) 2004 ·Journal of the American College of Cardiology ·Marco Metra, Philip A. Poole‐Wilson, John G.F. Cleland, Andrea Di Lenarda, Peter Hanrath, Michel Komajda, Jacobus Lubsen, Beatrix Lutiger, Willem J. Remme, Armin Scherhag, Andrew Charlesworth, Christian Torp‐Pedersen	3
13	835-4 Comparison of the effects of metoprolol and carvedilol on symptoms, well-being, and quality-adjusted life-years: A description of the patient-journey in COMET 2004 ·Journal of the American College of Cardiology ·John G.F. Cleland, Karl Swedberg, Andrea Di Lenarda, Peter Hanrath, Michel Komajda, Beatrix Lutiger, Jacobus Lubsen, Marco Metra, Willem J. Remme, Armin Scherhag, Andrew Charlesworth, Christian Torp‐Pedersen, Philip A. Poole‐Wilson	3
14	842-2 Hemoglobin level is associated with mortality and hospitalization in patients with severe chronic heart failure: Results from the COPERNICUS study 2004 ·Journal of the American College of Cardiology ·Stefan D. Anker, Andrew J.S. Coats, Ellen B. Roecker, Paul Mohaçsi, Jean L. Rouleau, Henry Krum, Armin Scherhag, Milton Packer	3
15	Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure 2004 ·Journal of the American College of Cardiology ·Jean L. Rouleau, Ellen B. Roecker, Michał Tendera, Paul Mohaçsi, Henry Krum, Hugo A. Katus, Michael B. Fowler, Andrew J.S. Coats, A Castaigne, Armin Scherhag, Terry L. Holcslaw, Milton Packer	108
16	1012-121 Lack of heart rate effects on the mortality benefits of carvedilol compared to metoprolol in the patients with heart failure: Results from the carvedilol or metoprolol European trial (COMET) 2004 ·Journal of the American College of Cardiology ·Marco Metra, John G.F. Cleland, Andrea Di Lenarda, Peter Hanrath, Michel Komajda, Beatrix Lutiger, Philip A. Poole‐Wilson, Willem J. Remme, Armin Scherhag, Andrew Charlesworth, Karl Swedberg, Christian Torp‐Pedersen	2
17	Diagnostic value of stress echocardiography for the detection of restenosis after PTCA 2004 ·International Journal of Cardiology ·Armin Scherhag, Stefan Pfleger, (unknown), Tim Sueselbeck, Martin Borggrefe	11
18	835-2 Carvedilol better protects against vascular events than metoprolol in heart failure: Results from COMET 2004 ·Journal of the American College of Cardiology ·Willem J. Remme, John G.F. Cleland, Andrea Di Lenarda, Peter Hanrath, Beatrix Lutiger, Michel Komajda, Marco Metra, Armin Scherhag, Andrew Charlesworth, Christian Torp‐Pedersen	7
19	Replacement of angiotensin converting enzyme inhibition by carvedilol results in long-term reversed left ventricular remodeling in mild heart failure and is well tolerated: Results of the CARMEN (Carvedilol aceinhibitor remodeling in mild heart failure evaluation) study 2003 ·Journal of the American College of Cardiology ·Willem J. Remme, Jordi Soler‐Soler, Lars Rydén, Per Hildebrandt, Marco Bobbio, Wybren Jaarsma, Michel Komajda, Armin Scherhag, (unknown)	5
20	[Analgosedation (managed anesthesia care--MAC) with propofol and piritramide for controlled cyclophotocoagulation of the eye]. 2000 ·PubMed ·(unknown), Armin Scherhag, Paul‐Rolf Preußner	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact